Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Viemed Healthcare (VMD) EBITDA (2018 - 2025)

Viemed Healthcare (VMD) has disclosed EBITDA for 6 consecutive years, with $8.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA rose 29.74% year-over-year to $8.4 million, compared with a TTM value of $22.9 million through Dec 2025, up 32.66%, and an annual FY2025 reading of $22.9 million, up 103.72% over the prior year.
  • EBITDA was $8.4 million for Q4 2025 at Viemed Healthcare, up from $5.6 million in the prior quarter.
  • Across five years, EBITDA topped out at $8.4 million in Q4 2025 and bottomed at $1.0 million in Q2 2022.
  • Average EBITDA over 5 years is $3.3 million, with a median of $2.7 million recorded in 2022.
  • The sharpest move saw EBITDA tumbled 91.95% in 2021, then soared 150.13% in 2023.
  • Year by year, EBITDA stood at $4.1 million in 2021, then tumbled by 42.45% to $2.4 million in 2022, then skyrocketed by 45.97% to $3.5 million in 2023, then skyrocketed by 85.56% to $6.5 million in 2024, then increased by 29.74% to $8.4 million in 2025.
  • Business Quant data shows EBITDA for VMD at $8.4 million in Q4 2025, $5.6 million in Q3 2025, and $5.1 million in Q2 2025.